-
1
-
-
7244252991
-
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals
-
Acosta E.P., Wu H., Hammer S.M., Yu S., Kuritzkes D.R., Walawander A., et al. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. Journal of Acquired Immune Deficiency Syndromes 37 (2004) 1358-1366
-
(2004)
Journal of Acquired Immune Deficiency Syndromes
, vol.37
, pp. 1358-1366
-
-
Acosta, E.P.1
Wu, H.2
Hammer, S.M.3
Yu, S.4
Kuritzkes, D.R.5
Walawander, A.6
-
2
-
-
0037339136
-
The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy
-
Becker S.L. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opinion on Investigational Drugs 12 (2003) 401-412
-
(2003)
Expert Opinion on Investigational Drugs
, vol.12
, pp. 401-412
-
-
Becker, S.L.1
-
3
-
-
33847335433
-
-
Boehringer Ingelheim Pharmaceuticals, Inc. (2005). Tipranavir [package insert]. Ridgefield, CT: Author.
-
-
-
-
4
-
-
1542613860
-
Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: Immunovirological outcome and side effects
-
Bongiovanni M., Bini T., Chiesa E., Cicconi P., Adorni F., and Monforte d'Arminio A. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: Immunovirological outcome and side effects. Antiviral Research 62 (2004) 53-56
-
(2004)
Antiviral Research
, vol.62
, pp. 53-56
-
-
Bongiovanni, M.1
Bini, T.2
Chiesa, E.3
Cicconi, P.4
Adorni, F.5
Monforte d'Arminio, A.6
-
5
-
-
33645498764
-
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)
-
Boyd M.A., Srasuebkul P., Khongphattanayothin M., Ruxrungtham K., Hassink E.A.M., Duncombe C.J., et al. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 2006 11 (2006) 223-232
-
(2006)
Antiviral Therapy, 2006
, vol.11
, pp. 223-232
-
-
Boyd, M.A.1
Srasuebkul, P.2
Khongphattanayothin, M.3
Ruxrungtham, K.4
Hassink, E.A.M.5
Duncombe, C.J.6
-
6
-
-
33847304903
-
-
Bristol-Myers Squibb. (2005). Atazanavir [package insert]. Princeton, NJ: Author.
-
-
-
-
7
-
-
33847289174
-
-
Brown T. T., Cole S. R., Li X., Kingsley L. A., Palella F. J., Jr., Riddler S. A., et al. (2004, February). Prevalence and incidence of pre-diabetes and diabetes in the Multicenter AIDS Cohort Study. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
-
-
-
-
8
-
-
19344373051
-
Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study
-
Brown T.T., Cole S.R., Li X., Kingsley L.A., Palella F.J., Riddler S.A., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Archives of Internal Medicine 165 (2005) 1179-1184
-
(2005)
Archives of Internal Medicine
, vol.165
, pp. 1179-1184
-
-
Brown, T.T.1
Cole, S.R.2
Li, X.3
Kingsley, L.A.4
Palella, F.J.5
Riddler, S.A.6
-
9
-
-
0032971472
-
Ritonavir and saquinavir combination therapy for the treatment of HIV infection
-
Cameron D.W., Japour A.J., Xu Y., Hsu A., Mellors J., Farthing C., et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13 (1999) 213-224
-
(1999)
AIDS
, vol.13
, pp. 213-224
-
-
Cameron, D.W.1
Japour, A.J.2
Xu, Y.3
Hsu, A.4
Mellors, J.5
Farthing, C.6
-
10
-
-
0033200240
-
The rabbit study: Ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients
-
Churchill D.R., Pym A.S., Galpin S., Foxall R., Stainsby C., Clarke J.R., et al. The rabbit study: Ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. AIDS Research and Human Retroviruses 15 (1999) 1181-1189
-
(1999)
AIDS Research and Human Retroviruses
, vol.15
, pp. 1181-1189
-
-
Churchill, D.R.1
Pym, A.S.2
Galpin, S.3
Foxall, R.4
Stainsby, C.5
Clarke, J.R.6
-
11
-
-
33847251486
-
-
Clumeck N., Brun S., Sylte J., Isaacson J., Chen S., Lazzarin A., et al. (2001, February). Kaletra (ABT-378/r) and efavirenz: One-year safety/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patients. Paper presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. Abstract No. 525.
-
-
-
-
13
-
-
0002764694
-
Drug biotransformation
-
Katzung B.G. (Ed), Lange Medical Books/McGraw-Hill, Medical Publishing Division, New York
-
Correia M.A. Drug biotransformation. In: Katzung B.G. (Ed). Basic & clinical pharmacology. 9th ed. (2004), Lange Medical Books/McGraw-Hill, Medical Publishing Division, New York
-
(2004)
Basic & clinical pharmacology. 9th ed.
-
-
Correia, M.A.1
-
14
-
-
0037251643
-
Lopinavir/ritonavir: A review of its use in the management of HIV infection
-
Cvetkovic R.S., and Goa K.L. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 63 (2003) 769-802
-
(2003)
Drugs
, vol.63
, pp. 769-802
-
-
Cvetkovic, R.S.1
Goa, K.L.2
-
15
-
-
33847282803
-
-
DeJesus E., Grinsztejn B., Rodriguez C., Nieto-Cisneros L., Coco J., Lazzarin A., et al. (2004, February). Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) vs. lopinavir/ritonavir (LPV/RTV) in patients who have experienced virologic failure on multiple HAART regimens: 48-week results from BMS AI424-045. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA. Abstract No. 547.
-
-
-
-
16
-
-
33847299890
-
-
DeJesus E., LaMarca A., Sension M., Beltran C., Yeni P. (2003, February). The CONTEXT study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
-
-
-
-
17
-
-
0141612910
-
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 Trial
-
Dragsted U.B., Gerstoft J., Pedersen C., Peters B., Duran A., Obel N., et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 Trial. Journal of Infectious Diseases 188 (2003) 635-642
-
(2003)
Journal of Infectious Diseases
, vol.188
, pp. 635-642
-
-
Dragsted, U.B.1
Gerstoft, J.2
Pedersen, C.3
Peters, B.4
Duran, A.5
Obel, N.6
-
18
-
-
33847299395
-
-
Elston, R. C., Yates, P., Tisdale, M., Richards, N., White, S., DeJesus, E. (2004, July). GW433908 (908)/ritonavir (r): 48 week results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype. Paper presented at the XV International AIDS Conference, Bangkok, Thailand. Abstract No. MoOrB1055. Retrieved January 14, 2005, from http://www.iasociety.org/ejias
-
-
-
-
19
-
-
0034128937
-
Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits
-
Flexner C. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits. Annual Review of Pharmacology and Toxicology 40 (2000) 649-674
-
(2000)
Annual Review of Pharmacology and Toxicology
, vol.40
, pp. 649-674
-
-
Flexner, C.1
-
20
-
-
12144286934
-
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?
-
Fontas E., van Leth F., Sabin C.A., Friis-Moller N., Rickenbach M., d'Arminio Monforte A., et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?. Journal of Infectious Diseases 189 (2004) 1056-1074
-
(2004)
Journal of Infectious Diseases
, vol.189
, pp. 1056-1074
-
-
Fontas, E.1
van Leth, F.2
Sabin, C.A.3
Friis-Moller, N.4
Rickenbach, M.5
d'Arminio Monforte, A.6
-
21
-
-
0345064200
-
Combination antiretroviral therapy and the risk of myocardial infarction
-
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
-
Friis-Moller N., Sabin C.A., Weber R., d'Arminio Monforte, A El-Sadr W.M., Reiss P., et al., Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine 349 (2003) 1993-2003
-
(2003)
New England Journal of Medicine
, vol.349
, pp. 1993-2003
-
-
Friis-Moller, N.1
Sabin, C.A.2
Weber, R.3
d'Arminio Monforte4
A El-Sadr, W.M.5
Reiss, P.6
-
22
-
-
2042469458
-
Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome
-
Gianotti N., Soria A., Galli L., Giudici B., Fusetti G., Lazzarin A., et al. Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome. AIDS 18 (2004) 821-823
-
(2004)
AIDS
, vol.18
, pp. 821-823
-
-
Gianotti, N.1
Soria, A.2
Galli, L.3
Giudici, B.4
Fusetti, G.5
Lazzarin, A.6
-
23
-
-
17044457456
-
Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens
-
Gutierrez F., Padilla S., Navarro A., Masia M., Hernandez I., Ramos J., et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. Journal of Acquired Immune Deficiency Syndromes 33 (2003) 594-600
-
(2003)
Journal of Acquired Immune Deficiency Syndromes
, vol.33
, pp. 594-600
-
-
Gutierrez, F.1
Padilla, S.2
Navarro, A.3
Masia, M.4
Hernandez, I.5
Ramos, J.6
-
24
-
-
33847323406
-
-
Harley W., DeJesus E., Pistole M., Sension M., Garrett L., Nettler S., et al. (2001, February). A 24-week randomized, controlled, open-label evaluation of adherence and convenience of continuing indinavir versus switching to ritonavir/indinavir 400 mg/400 mg BID (The NICE Study). Paper presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. Abstract No. 334.
-
-
-
-
25
-
-
20144365012
-
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results
-
Kashuba A.D., Tierney C., Downey G.F., Acosta E.P., Vergis E.N., Klingman K., et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 19 (2005) 145-152
-
(2005)
AIDS
, vol.19
, pp. 145-152
-
-
Kashuba, A.D.1
Tierney, C.2
Downey, G.F.3
Acosta, E.P.4
Vergis, E.N.5
Klingman, K.6
-
26
-
-
33847305352
-
-
Katlama C., Arasteh K., Clotet B., Cooper D., Henry K., Lalezari J., et al. (2003, July). Enfuvirtide TORO studies: 48 week results confirm 24 week findings. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France. Abstract No. LB02.
-
-
-
-
27
-
-
33847315495
-
-
Katlama C., Berger D., Bellos N., Grinsztejn B., Haubrich R., Wilkin T., et al. (2005, February). Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA. Abstract No. 164LB.
-
-
-
-
28
-
-
0037648770
-
Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers
-
Kurowski M., Sternfeld T., Sawyer A., Hill A., and Mocklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Medicine 4 (2003) 94-100
-
(2003)
HIV Medicine
, vol.4
, pp. 94-100
-
-
Kurowski, M.1
Sternfeld, T.2
Sawyer, A.3
Hill, A.4
Mocklinghoff, C.5
-
29
-
-
1642315800
-
The metabolic effects of lopinavir/ritonavir in HIV-negative men
-
Lee G.A., Seneviratne T., Noor M.A., Lo J.C., Schwarz J.M., Aweeka F.T., et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 18 (2004) 641-649
-
(2004)
AIDS
, vol.18
, pp. 641-649
-
-
Lee, G.A.1
Seneviratne, T.2
Noor, M.A.3
Lo, J.C.4
Schwarz, J.M.5
Aweeka, F.T.6
-
30
-
-
33847299949
-
-
Lundgren J. D., Hill A., Fox Z., Clumeck N., Bruun J. N., Benetucci J., et al on behalf of the MaxCmin Trial Group. (2003, July). Hepatotoxicity of ritonavir-boosted indinavir (IDV/r 800/100 mg twice daily) and saquinavir (SAQ/r 1000/100 mg twice daily) in a phase IV, randomized, open-label, and multicentre trial in adult HIV-1 infection: the MaxCmin1 Trial. Paper presented at the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, France.
-
-
-
-
31
-
-
11144357725
-
Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir
-
Martinez E., Domingo P., Galindo M.J., Milinkovic A., Arroyo J.A., Baldori F., et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clinical Infectious Diseases 38 (2004) 1017-1023
-
(2004)
Clinical Infectious Diseases
, vol.38
, pp. 1017-1023
-
-
Martinez, E.1
Domingo, P.2
Galindo, M.J.3
Milinkovic, A.4
Arroyo, J.A.5
Baldori, F.6
-
32
-
-
1642403331
-
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men
-
Clinical Epidemiology Group from the French Hospital Database (2003)
-
Mary-Krause M., Cotte L., Simon A., Partisani M., Costagliola D., and Clinical Epidemiology Group from the French Hospital Database (2003). Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17 (2003) 2479-2486
-
(2003)
AIDS
, vol.17
, pp. 2479-2486
-
-
Mary-Krause, M.1
Cotte, L.2
Simon, A.3
Partisani, M.4
Costagliola, D.5
-
33
-
-
33847253339
-
-
McCallister S., Kohlbrenner V., Villacian J., Mukwaya G., Neubacher D., Mayers D. (2004, December). 24-week combined analysis for the TPV RESIST studies of 1483 treatment-experienced patients given either tipranavir/ritonavir (TPV/r) or an optimized standard of care regimen using 1 of 4 RTV-boosted comparator PIs (CPI/r). Paper presented at the HIV DART 2004, Montego Bay, Jamaica. Abstract No. 060.
-
-
-
-
34
-
-
33847322938
-
-
Neubacher D., Markowitz M., Slater L., Curry R., Mayers D., McCallister S. (2003, October). Long-term 80-week follow-up of highly treatment-experienced (HTE) patients on tipranavir-based antiretroviral therapy (BI 1182.2). Paper presented at the 9th European AIDS Conference, Warsaw, Poland.
-
-
-
-
36
-
-
2642709177
-
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
-
Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338 (1998) 853-860
-
(1998)
New England Journal of Medicine
, vol.338
, pp. 853-860
-
-
Palella Jr., F.J.1
Delaney, K.M.2
Moorman, A.C.3
Loveless, M.O.4
Fuhrer, J.5
Satten, G.A.6
-
37
-
-
33847266189
-
-
Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. May 4, 2006. Retrieved June 13, 2006, from http://aidsinfo.nih.gov/guidelines
-
-
-
-
38
-
-
33644661382
-
Evaluation of coronary artery calcification by electron beam computed tomography (EBCT) in HIV-infected men receiving prolonged protease inhibitor (PI) therapy
-
Abstract No. 116
-
Parenti D.M., Klouj A., Rice M.M., Roberts A.D., Liappis A.P., Bisby N., et al. Evaluation of coronary artery calcification by electron beam computed tomography (EBCT) in HIV-infected men receiving prolonged protease inhibitor (PI) therapy. Antiviral Therapy 9 (2004) L65 Abstract No. 116
-
(2004)
Antiviral Therapy
, vol.9
-
-
Parenti, D.M.1
Klouj, A.2
Rice, M.M.3
Roberts, A.D.4
Liappis, A.P.5
Bisby, N.6
-
39
-
-
33847318612
-
-
Podzamczer D., Tressler R., Flexner C., Katlama C., Havlir D., Letendre S., et al. (2004, July). Higher doses of lopinavir/ritonavir (LPV/r) in highly treatment-experienced, HIV-infected patients: 48-week safety/efficacy evaluation. Poster presented at the 15th International AIDS Conference, Bangkok, Thailand. Poster TuPeB4555.
-
-
-
-
41
-
-
10244222704
-
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir
-
Sulkowski M.S., Mehta S.H., Chaisson R.E., Thomas D.L., and Moore R.D. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 18 (2004) 2277-2284
-
(2004)
AIDS
, vol.18
, pp. 2277-2284
-
-
Sulkowski, M.S.1
Mehta, S.H.2
Chaisson, R.E.3
Thomas, D.L.4
Moore, R.D.5
-
42
-
-
17344370085
-
Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection
-
Visnegarwala F., Chen L., Raghavan S., and Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. Journal of Infection 50 (2005) 331-337
-
(2005)
Journal of Infection
, vol.50
, pp. 331-337
-
-
Visnegarwala, F.1
Chen, L.2
Raghavan, S.3
Tedaldi, E.4
-
43
-
-
0034493003
-
Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests
-
Vora S., Michon C., Junet C., Belavoine J.F., Renold-Moynier C., Yerly S., et al. Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests. AIDS 14 (2000) 2795-2797
-
(2000)
AIDS
, vol.14
, pp. 2795-2797
-
-
Vora, S.1
Michon, C.2
Junet, C.3
Belavoine, J.F.4
Renold-Moynier, C.5
Yerly, S.6
-
44
-
-
0032558803
-
Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
-
Walli R., Herfort O., Michl G.M., Demant T., Jager H., Dieterle C., et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. IDS 12 (1998) F167-F173
-
(1998)
IDS
, vol.12
-
-
Walli, R.1
Herfort, O.2
Michl, G.M.3
Demant, T.4
Jager, H.5
Dieterle, C.6
-
45
-
-
33847291722
-
-
Walmsley S., Benetucci J., Brutus A., Clumeck N., Dragsted U. B., Gazzard, B, et al. (2004, February). Lipid profiles of patients enrolled in the MaxCmin2 trial: A randomized, open-label, multicenter comparative trial evaluating the safety and efficacy of lopinavir/ritonavir (LPV/r; 400/100 MG bid) versus saquinavir/ritonavir (SAQ/r; 1000/100 MG bid). Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
-
-
-
-
46
-
-
33847277022
-
-
Weber R., Friis-Moller N., Sabin C., Reiss P., D'Arminio Monforte A., Dabis F., et al. (2005, February). HIV and non-HIV-related deaths and their relationship to immunodeficiency: The D:A:D Study. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
-
-
-
-
47
-
-
0141458274
-
Tipranavir: A protease inhibitor from a new class with distinct antiviral activity
-
Yeni P. Tipranavir: A protease inhibitor from a new class with distinct antiviral activity. Journal of Acquired Immune Deficiency Syndrome 34 Suppl. 1 (2003) S91-S94
-
(2003)
Journal of Acquired Immune Deficiency Syndrome
, vol.34
, Issue.SUPPL. 1
-
-
Yeni, P.1
|